New Investigational Medications for MDD

New Investigational Medications for MDD

Q: Which of the following novel investigational medication used "Intranasally" has shown positive and rapid response in research patients with MDD?
(a) GLYX 13
(b) Onabotulinumtoxin A (OBA)
(c) PH 10
(d) Vortioxetine

Admin wrote:New Investigational Medications for MDD

Q: Which of the following novel investigational medication used "Intranasally" has shown positive and rapid response in research patients with MDD?
(a) GLYX 13
(b) Onabotulinumtoxin A (OBA)
(c) PH 10
(d) Vortioxetine

Ans: (c) PH 10.
An exploratory Phase 2A randomized study was conducted in 30 patients diagnosed with Major Depression, to compare the efficacy and safety of 400 and 800 nanogram PH10 and placebo administered intranasally in spray form. Patients self administered PH10 nasal spray up to 4 times daily during 9 consecutive weeks and were evaluated in the clinic at the end of each treatment week, using validated psychometric instruments.
The preliminary analysis of the results shows significant dose dependent effect of PH10 nasal spray on Hamilton Depression scores, which is different from the effect of treatment with placebo. The clinical efficacy of 800 nanogram PH10 nasal spray on Hamilton Depression scores was greater than that of 400-nanogram PH10, increased progressively starting on the first day of treatment and continued along the 98-week treatment period. The rapid onset of effect of PH10 nasal spray reported in the present study is very promising and may help mitigate the symptoms of depression with a much faster onset of action than conventional antidepressants.

GLYX-13:
NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.
Studies with infusion of GLYX-13 as antidepressant is going on.
Source: http://www.ncbi.nlm.nih.gov/pubmed/23303054

Onabotulinumtoxin A (OBA):
injection at glabellar region with OBA induces sustained alleviation of symptoms on pt with MDD.

Vortioxetine:
Modulation of GABAergic activity via 5-HT3 receptor antagonism. Unlike SSRIs or SNRIs, vortioxetine has a multimodal mode action that is thought to work through a combination of two complementary mechanisms of action: receptor activity modulation and reuptake inhibition.